CN110292638A - 治疗轻度和中度阿尔茨海默病的方法 - Google Patents

治疗轻度和中度阿尔茨海默病的方法 Download PDF

Info

Publication number
CN110292638A
CN110292638A CN201910466681.3A CN201910466681A CN110292638A CN 110292638 A CN110292638 A CN 110292638A CN 201910466681 A CN201910466681 A CN 201910466681A CN 110292638 A CN110292638 A CN 110292638A
Authority
CN
China
Prior art keywords
day
hydrochloride
disease
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910466681.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.奥兰迪
D.J.克拉克
I.M.格里梅斯
M.C.瓦尔卡西-洛佩兹
M.J.考斯图拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of CN110292638A publication Critical patent/CN110292638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CN201910466681.3A 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法 Pending CN110292638A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
US61/710,229 2012-10-05
CN201380051206.0A CN104703592A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380051206.0A Division CN104703592A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN110292638A true CN110292638A (zh) 2019-10-01

Family

ID=49354960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910466681.3A Pending CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法
CN201380051206.0A Pending CN104703592A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380051206.0A Pending CN104703592A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Country Status (15)

Country Link
EP (1) EP2903606A1 (https=)
JP (2) JP6566868B2 (https=)
KR (1) KR20150064743A (https=)
CN (2) CN110292638A (https=)
AU (2) AU2013327450B2 (https=)
BR (1) BR112015007641A8 (https=)
CA (1) CA2886785C (https=)
EA (1) EA201590687A1 (https=)
HK (1) HK1207004A1 (https=)
IL (1) IL237730B (https=)
IN (1) IN2015DN03734A (https=)
MX (1) MX377733B (https=)
NZ (2) NZ705813A (https=)
SG (2) SG10201702648YA (https=)
WO (1) WO2014055588A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114957470A (zh) * 2021-11-12 2022-08-30 深圳市人民医院 靶向rage的纳米抗体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
CN101171009A (zh) * 2005-04-01 2008-04-30 生物计划公司 用非咪唑烷基胺组胺h3－受体的配体治疗帕金森症、阻塞性睡眠呼吸暂停、路易体痴呆、血管性痴呆
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681864A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
CN101171009A (zh) * 2005-04-01 2008-04-30 生物计划公司 用非咪唑烷基胺组胺h3－受体的配体治疗帕金森症、阻塞性睡眠呼吸暂停、路易体痴呆、血管性痴呆
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARWAN N.SABBAGH ET AL.: "PF-04494700,an oral inhibitor of receptor for advanced glycation end products (RAGE),in Alzheimer disease.", 《ALZHEIMER DIS ASSOC DISORD》 *
PFIZER: "《NCT00566397》", 31 December 2010, HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT00566397?TERM=NCT00566397&DRAW=2&RANK=1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114957470A (zh) * 2021-11-12 2022-08-30 深圳市人民医院 靶向rage的纳米抗体及其应用
CN114957470B (zh) * 2021-11-12 2023-01-17 深圳市人民医院 靶向rage的纳米抗体及其应用

Also Published As

Publication number Publication date
BR112015007641A2 (pt) 2017-07-04
EA201590687A1 (ru) 2015-09-30
EP2903606A1 (en) 2015-08-12
AU2013327450A1 (en) 2015-05-14
AU2018203434A1 (en) 2018-06-07
CA2886785A1 (en) 2014-04-10
SG10201702648YA (en) 2017-04-27
IN2015DN03734A (https=) 2015-09-18
WO2014055588A1 (en) 2014-04-10
JP2015535850A (ja) 2015-12-17
CA2886785C (en) 2022-06-07
JP6894940B2 (ja) 2021-06-30
IL237730B (en) 2018-10-31
SG11201502210VA (en) 2015-04-29
NZ705813A (en) 2018-02-23
MX377733B (es) 2025-03-11
JP6566868B2 (ja) 2019-08-28
CN104703592A (zh) 2015-06-10
BR112015007641A8 (pt) 2018-04-03
HK1207004A1 (zh) 2016-01-22
NZ739521A (en) 2019-06-28
MX2015003732A (es) 2015-09-23
JP2019163301A (ja) 2019-09-26
AU2013327450B2 (en) 2018-07-12
KR20150064743A (ko) 2015-06-11

Similar Documents

Publication Publication Date Title
JP6894940B2 (ja) 軽度および中等度アルツハイマー病の処置
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
Richter et al. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus
Ueki et al. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
EP2364146B1 (en) Medicament and method of diagnosis
US20190142803A1 (en) Treatment of Mild and Moderate Alzheimer's Disease
US20210113495A1 (en) Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
Pringle et al. Severe bradycardia due to interaction of timolol eye drops and verapamil
JP2018138572A (ja) 疾患および障害を検出、治療、および予防するための組成物および方法
Trailokya et al. Naftifine: a topical allylamine for superficial dermatophytosis
Connelly et al. The SGLT2i dapagliflozin reduces RV mass independent of changes in RV pressure induced by pulmonary artery banding
CN117460517A (zh) 用于预防或治疗犬科动物糖尿病的含有依那格列净的药物组合物
Ghazali et al. Plasma methadone level monitoring in methadone maintenance therapy: A personalised methadone therapy
HK40009571A (zh) 治疗轻度和中度阿尔茨海默病的方法
CN102727494B (zh) 一种治疗皮肤真菌感染的外用药物组合物
AU2023302938A1 (en) Composition for intermittent dosing of calcineurin inhibitors
CN105250268B (zh) 厄贝沙坦组合物及其在制备治疗急性肾损伤的药物中的应用
Zaremba-Pechmann et al. Ronald Dahl, Michael Engel b, Daniel Dusser c, David Halpin d, Huib AM Kerstjens e
HK40061328B (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
Hart et al. Developing pharmacotherapies for cannabis and cocaine use disorders
WO2020169041A1 (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
Rapihaler Australian Public Assessment Report for Budesonide/eformoterol fumarate dihydrate
Gupta et al. POTENTIAL TARGETS FOR EFFECTIVE THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DIABETIC NEPHROPATHY
Yang Effect of Metformin on Tyrosine Kinase Autophosphorylation of Erythrocyte Insulin Receptor from Women with Polycystic Ovary Syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009571

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191001

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40009571

Country of ref document: HK